- Home
- AMLX vs UPB Comparison
AMLX vs UPB Comparison
Compare AMLX & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- UPB
- Stock Information
- Founded
- AMLX 2014
- UPB 2021
- Country
- AMLX United States
- UPB United States
- Employees
- AMLX N/A
- UPB N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- UPB
- Sector
- AMLX Health Care
- UPB
- Exchange
- AMLX Nasdaq
- UPB NYSE
- Market Cap
- AMLX 459.1M
- UPB 521.3M
- IPO Year
- AMLX 2022
- UPB 2024
- Fundamental
- Price
- AMLX $5.05
- UPB $10.88
- Analyst Decision
- AMLX Buy
- UPB Strong Buy
- Analyst Count
- AMLX 6
- UPB 4
- Target Price
- AMLX $10.17
- UPB $56.50
- AVG Volume (30 Days)
- AMLX 911.0K
- UPB 422.3K
- Earning Date
- AMLX 08-07-2025
- UPB 08-14-2025
- Dividend Yield
- AMLX N/A
- UPB N/A
- EPS Growth
- AMLX N/A
- UPB N/A
- EPS
- AMLX N/A
- UPB N/A
- Revenue
- AMLX N/A
- UPB $2,296,000.00
- Revenue This Year
- AMLX N/A
- UPB N/A
- Revenue Next Year
- AMLX N/A
- UPB N/A
- P/E Ratio
- AMLX N/A
- UPB N/A
- Revenue Growth
- AMLX N/A
- UPB N/A
- 52 Week Low
- AMLX $1.62
- UPB $5.14
- 52 Week High
- AMLX $7.27
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- AMLX 48.04
- UPB N/A
- Support Level
- AMLX $5.24
- UPB N/A
- Resistance Level
- AMLX $5.66
- UPB N/A
- Average True Range (ATR)
- AMLX 0.34
- UPB 0.00
- MACD
- AMLX -0.05
- UPB 0.00
- Stochastic Oscillator
- AMLX 21.97
- UPB 0.00
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.